Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas

Neuro-Oncology

Volumn 14, Issue 6, 2012, Pages 777-789

  Horbinski, Craig ^a   Nikiforova, Marina N ^b   Hagenkord, Jill M ^c   Hamilton, Ronald L ^b   Pollack, Ian F ^d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Complete Genomics ^*  (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

BRAF; MIB1; p16; p53; V600E

Indexed keywords

B RAF KINASE; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; BASAL GANGLION; BRAIN STEM; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; DIENCEPHALON; FEMALE; GENE DELETION; GENE REARRANGEMENT; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; MESENCEPHALON; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PILOCYTIC ASTROCYTOMA; PLEOMORPHIC XANTHOASTROCYTOMA; PRESCHOOL CHILD; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SPINAL CORD; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; GENE REARRANGEMENT; GLIOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; MALE; NEOPLASM GRADING; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; YOUNG ADULT;

EID: 84862193195     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos077     Document Type: Article

References (35)

1. Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2008;67:878-887.
2. Pfister S. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008;118:1739-1749. (Pubitemid 351632377)
3. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673-8677.
4. Forshew T, Tatevossian RG, Lawson AR, et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol. 2009;218(2):172-181.
5. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene. 2009;28(20):2119-2123.
6. Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011;121(6):763-774.
7. Hawkins C, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res. 2011;17(14):4790-4798.
8. Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF. Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol. 2010;119(5):641-649.
9. Lawson AR, Tatevossian RG, Phipps KP, et al. RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort. Acta Neuropathol. 2010;120(2):271-273.
10. Sievert AJ, Jackson EM, Gai X, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 2009;19(3):449-458.
11. Huang H, Okamoto Y, Yokoo H, et al. Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene. 2004;23(35): 6012-6022. (Pubitemid 39093547)
12. Hasselblatt M, Riesmeier B, Lechtape B, et al. BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. Neuropathol Appl Neurobiol. 2011;37(7):803-806.
13. Schiffman JD, Hodgson JG, VandenBerg SR, et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010;70(2): 512-519.
14. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extracerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3): 397-405.
15. Dougherty MJ, Santi M, Brose MS, et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol. 2010;12(7):621-630.
16. Raabe EH, Lim KS, Kim JM, et al. BRAF activation induces transformation and then senescence in human neural stem cells: A pilocytic astrocytoma model. Clin Cancer Res. 2011;17(11):3590-3599.
17. Jacob K, Quang-Khuong DA, Jones DT, et al. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res. 2011;17(14):4650-4660.
18. Gronych J, Korshunov A, Bageritz J, et al. An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest. 2011;121(4):1344-1348.
19. Rodriguez EF, Scheithauer BW, Giannini C, et al. PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):407-420.
20. Pollack IF, Campbell JW, Hamilton RL, Martinez AJ, Bozik ME. Proliferation index as a predictor of prognosis in malignant gliomas of childhood. Cancer. 1997;79(4):849-856. (Pubitemid 27076352)
21. Pollack IF, Finkelstein SD, Burnham J, et al. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res. 2001;61(20):7404-7407. (Pubitemid 32995024)
22. Pollack IF, Finkelstein SD,Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346(6):420-427. (Pubitemid 34437697)
23. Pollack IF, Hamilton RL, Burnham J, et al. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery. 2002;50(6):1238-1244; discussion 1244-1235.
24. Pollack IF, Hamilton RL, Finkelstein SD, et al. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res. 1997;57(2):304-309. (Pubitemid 27036787)
25. Margraf LR, Gargan L, Butt Y, Raghunathan N, Bowers DC. Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas-an assessment of 3 new variables in predicting clinical outcome. Neuro Oncol. 2011;13(7):767-774.
26. Horbinski C, Hamilton RL, Lovell C, Burnham J, Pollack IF. Impact of morphology, MIB-1, p53 and MGMT on outcome in pilocytic astrocytomas. Brain Pathol. 2009;20(3):581-588.
27. Pollack IF, Hamilton RL, Sobol RW, et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol. 2006;24(21):3431-3437. (Pubitemid 46638900)
28. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005;115(1):94-101. (Pubitemid 40385509)
29. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94(6): 2092-2098.
30. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
31. Nicolaides T, Li H, Solomon D, et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res. 2011;17(24): 7595-7604.
32. Rasheed A, Herndon JE, Stenzel TT, et al. Molecular markers of prognosis in astrocytic tumors. Cancer. 2002;94(10):2688-2697. (Pubitemid 34478085)
33. Giannini C, Scheithauer BW, Burger PC, et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol. 1999;58(1):46-53. (Pubitemid 29053025)
34. Tihan T, Ersen A, Qaddoumi I, et al. Pathologic Characteristics of pediatric intracranial pilocytic astrocytomas and their impact on outcome in 3 countries: a multi-institutional study. Am J Surg Pathol. 2011; 36(1):43-55.
35. Cheng Y, Pang JC, Ng HK, et al. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas. Histopathology. 2000;37(5):437-444.